WO2024241229 - NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
National phase entry:
Publication Number
WO/2024/241229
Publication Date
28.11.2024
International Application No.
PCT/IB2024/054958
International Filing Date
22.05.2024
Title **
[English]
NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER
[French]
DÉRIVÉS DE NAPHTYRIDINONE POUR LE TRAITEMENT D'UNE MALADIE OU D'UN TROUBLE
Applicants **
NOVARTIS AG
Inventors
CHEUNG, Atwood
LIU, Donglei
PEUKERT, Stefan
TRAUGER, John
Priority Data
63/504,099
24.05.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2478 | |
| EPO | Filing, Examination, Granting | 11052 | |
| Japan | Filing, Examination, Granting | 2276 | |
| South Korea | Filing, Examination, Granting | 2199 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
23,945
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to a compound which is a phosphoric acid ester derivative of a compound of formula (I): (I) wherein A, L and R3 are as described herein, as well as compositions and methods of using such compound.[French]
La présente invention concerne un composé qui est un dérivé d'ester d'acide phosphorique d'un composé de formule (I) : (I) dans laquelle A, L et R3 sont tels que décrits dans la description, ainsi que des compositions et des procédés d'utilisation d'un tel composé.